论文部分内容阅读
目的探讨晚期氧化蛋白产物(AOPP)能否预测DR进展情况。方法采用前瞻性队列研究方法纳入T2DM患者363例,根据基线AOPP水平四分位点将受试者分为4组(Q1、Q2、Q3、Q4),根据5年随访前后免散瞳眼底摄片结果计算DR进展率。结果随基线AOPP水平升高,5年后DR进展率升高(19.51%vs 28.42%vs 37.36%vs 47.37%,P<0.01)。Logistic回归分析显示,基线AOPP水平是影响DR进展的独立危险因素(OR=1.833,95%CI:1.573~1.982,P<0.05)。基线AOPP水平预测5年后DR进展的曲线下面积(AUC)为0.883(95%CI:0.842~0.924),敏感性和特异性分别为86.1%、91.9%。结论 AOPP可能是预测DR进展的生物标记物之一。
Objective To investigate whether advanced oxidation protein product (AOPP) can predict the progression of DR. Methods A total of 363 T2DM patients were enrolled in the prospective cohort study. Subjects were divided into 4 groups (Q1, Q2, Q3 and Q4) according to the baseline AOPP quartile. Results The rate of DR progression was calculated. Results With the increase of baseline AOPP level, the progression rate of DR increased after 5 years (19.51% vs 28.42% vs 37.36% vs 47.37%, P <0.01). Logistic regression analysis showed that baseline AOPP level was an independent risk factor for the progression of DR (OR = 1.833, 95% CI: 1.573-1.982, P <0.05). The area under the curve (AUC) of baseline AOPP level at 5 years after DR prediction was 0.883 (95% CI: 0.842-0.924) with a sensitivity and specificity of 86.1% and 91.9%, respectively. Conclusion AOPP may be one of the biomarkers for predicting the progression of DR.